Evidence map›Paper›PMID 42287037›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026

[Evaluation of bilateral vaccine cooperation priority countries on Chinese human papillomavirus vaccine using hierarchical K-means hybrid clustering].

Yinge Wu, Yangmu Huang

Abstract readEnglish Abstract
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yinge WuDepartment of Global Health, Peking University School of Public Health, Beijing 100191, China.
Yangmu HuangDepartment of Global Health, Peking University School of Public Health, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate priority target countries and formulate context-specific cooperation modalities for China ' s bilateral international collaboration on human papillomavirus (HPV) vaccines, thereby furnishing an evidence-based reference for optimizing China ' s bilateral vaccine cooperation stra-tegies and contributing to global health equity.

methodsUsing a previously established index system designed for selecting preferred countries in China ' s international vaccine cooperation, we comprehensively applied a weighted-scoring approach to quantitatively rank 29 Phases 3 and 4 Global Alliance for Vaccines and Immunization (Gavi) eligible countries in HPV vaccine cooperation. Based on 5 first-level index (legal and regulatory factors, economic factors, political factors, social factors, and technological factors) scores, a hierarchical K-means hybrid method was used for clustering the countries. Hierarchical clustering was initially utilized to explore the underlying data structure and determine the optimal number of clusters, followed by K-means clustering to precisely categorize the evaluated nations based on their multidimensional characteristics.

resultsThe top10 countries were mostly Asian countries. African countries were mostly in the lower ranks. The countries were clustered into three types: (1) Technology transfer priority (

conclusionIndonesia, Viet Nam, and Uzbekistan are identified as the priority target countries for China ' s bilateral international cooperation on HPV vaccines. For these technology-transfer priority nations, cooperation should be strategically conducted through diverse modalities encompassing vaccine product export, clinical trial collaboration, authorized licensing, and technology transfer.

Indexed as

Immunization ProgramsInternational CooperationPapillomavirus InfectionsPapillomavirus VaccinesChinaCluster AnalysisClustering AlgorithmsHumansPapillomavirus VaccinesCluster analysisHierarchical clusteringHuman papillomavirus vaccineInternational cooperationK-means clustering

Identifiers

PMID42287037
PMCPMC13268818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.